Medical/Pharmaceuticals

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

* CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing EYLUXVI® to the reference product Eylea® * Upon approval, EYLUXVI® will be Alteogen's second biosimilar product, following a Herceptin® biosimilar by Alteogen's license partner Qilu Pharm...

2025-07-28 14:00 1912

NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer

HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with ...

2025-07-28 12:14 3606

Ascletis Announces First Participants with Obesity or Overweight Dosed in Its U.S. 12-week Phase IIa Study Evaluating Once-Monthly Subcutaneous Depot Formulation of Small Molecule GLP-1R Agonist ASC30

-          First participants with obesity or overweight with at least one w eight-related comorbidity have been dosed in a U.S. 12-week Phase IIa study with once-monthly subcutaneous (SQ) depot formulation of small molecule GLP-1  receptor agonist ASC30. -          Ultra-long-acting SQ depot for...

2025-07-28 08:15 2124

Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 27, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced a positive prof...

2025-07-28 08:11 2218

Phase II Stage Of Pivotal Clinical Trial Of KX-826 Tincture 1.0% For The Treatment Of Male Adult Aga In China Reached Primary Endpoint

SUZHOU, China, July 25, 2025 /PRNewswire/ -- The Kintor Pharmaceutical Limited (the "Company") is pleased to announce that the Phase II Stage of the Pivotal Clinical Trial of its in-house developed and potential first-in-class KX-826 tincture 1.0% for the treatment of AGA has obtained top-line re...

2025-07-25 20:30 3532

OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology

BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and wellness innovation, today announced it has signed a term sheet ("Term Sheet") with Woori IO Co., Ltd. ("WORIO"), a South Korean medical de...

2025-07-24 19:30 2387

Fapon at ADLM 2025: One-stop IVD Solutions & Deepened US Commitment

CHICAGO, July 24, 2025 /PRNewswire/ -- Fapon, a global leader in life sciences, will unveil its innovative one-stop IVD solutions at ADLM 2025, fromJuly 29 to 31 in Chicago, IL. Fapon aims to be the trusted global partner for laboratories and IVD manufacturers with advanced innovations and dedica...

2025-07-24 19:00 2003

Akeso Announces First Patient Enrollment in Phase III Trial of Ivonescimab for Pancreatic Cancer

HONG KONG, July 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody dev...

2025-07-24 09:14 1505

HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma

* Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 * HBM9378/WIN378 has the potential to be the first-to-market long-acting anti-TSLP antibody with twice-yearly dosing for asthma ...

2025-07-23 20:36 2226

Zylox-Tonbridge Issues Positive Profit Alert, Expects Over RMB 115 Million in 1H 2025 Net Profit

HANGZHOU, China, July 23, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, "Zylox-Tonbridge" or the "Company"), a leading medical device company inChina's peripheral and neurovascular interventional market, today announced a positive profit alert for the six months ...

2025-07-23 14:57 2268

Samsung Biologics reports second quarter 2025 financial results

* Recorded Q2'25 consolidated revenue of KRW 1,289.9 billion * Recorded Q2'25 consolidated operating profit of KRW 475.6 billion * Solid momentum sustained through capacity ramp-up and stable project execution INCHEON, South Korea, July 23, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940...

2025-07-23 14:54 2246

A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US

All 20 US trial sites are now open in the XanaMIA phase 2b/3 trial that is studying oral Xanamem® vs. placebo for 36 weeks, followed by an open label extension of active Xanamem for up to 24 months SYDNEY, July 22, 2025 /PRNewswire/ -- Actinogen Medical Limited (ASX: ACW) is encouraging individu...

2025-07-22 20:00 2100

METiS Technologies Showcases AI-Powered Nanodelivery Platform at the 2025 Controlled Release Society Annual Meeting

HANGZHOU, BEIJING, China and CAMBRIDGE, Mass., July 22, 2025 /PRNewswire/ -- METiS Technologies, a global leader in AI-driven nanodelivery innovation, today announced the presentation of its latest research findings at the poster session of the 2025 Controlled Release Society (CRS) Annual Meeting...

2025-07-22 15:52 2591

DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation

SHANGHAI, July 21, 2025 /PRNewswire/ -- DualityBio (HKEX Stock Code: 9606.HK) announced thatthe U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to its next-generation HER3-targeting antibody-drug conjugate (ADC) DB-1310. This designation is for the treatment of ad...

2025-07-22 10:25 2312

2025 Inaugural Global Chest Wall Surgery Conference Concludes Successfully: Uniting Expertise, Driving Innovation

GUANGZHOU, China, July 21, 2025 /PRNewswire/ -- The inaugural Global Chest Wall Surgery Conference concluded successfully inGuangzhou on July 19, uniting leading medical experts worldwide to share cutting-edge surgical innovations and clinical insights inchest wall surgery

2025-07-21 22:33 1950

ICWS Successfully Concludes 2nd Global Program on Cutting-edge Chest Wall Surgery Techniques

GUANGZHOU, China, July 21, 2025 /PRNewswire/ -- The 2nd "Latest Chest Wall Surgery Technique Global Training Program", hosted bythe Institute of Chest Wall Surgery (ICWS) of Guangdong Second Provincial General Hospital, was successfully held fromJuly 16 to 18, 2025. Th...

2025-07-21 22:32 1724

BON Announces $22 Million Distribution Agreement for Weight Loss Products with Beijing Huahai Keyuan Technology Co., Ltd

XI'AN, China, July 21, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural health and personal care industries, today announced it has entered into a non-exclusive sales distribution agreement w...

2025-07-21 21:00 2823

Bloomage Achieves FDA GMP Audit with Zero-Deficiency, Reinforcing Global Trust

PARSIPPANY, N.J., July 21, 2025 /PRNewswire/ -- Bloomage, a global leader in hyaluronic acid and other bioactive substance innovations, has announced it successfully passed the U.S. Food and Drug Administration (FDA)'s on-site GMP audit with a "No Action Indicated" (NAI) result. This is the best ...

2025-07-21 21:00 1649

CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services

Strategic partnership to deliver transcriptomics-powered, organoid-based preclinical testing for high-impact drug discovery  SEOUL, South Korea, July 20, 2025 /PRNewswire/ -- CorestemChemon, a leading GLP-certified preclinical CRO based inSouth Korea, has entered into a strategic partnership wit...

2025-07-21 10:54 1716

Fangzhou and Novo Nordisk Signed Collaboration Memorandum to Establish a New Ecosystem for Health Management

BEIJING, July 18, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, signed a Memorandum of Understanding with Novo Nordisk, a leading global healthcare company, at the 3rd China International Supply Chain Expo in Beijing. Leve...

2025-07-18 20:04 2861
1 ... 26272829303132 ... 251

Week's Top Stories